Clinical evidence comes principally from three clinical trials and one retrospective cohort, all with modest sample sizes and heterogeneous populations, and without taking into consideration meaningful prognostic factors that have been identified over the last 10 years such as tumour sidedness, patient performance status or molecular biology including RAS/BRAF mutations [7, 39–41]. Here, BRAF is linked to neoplasm.